Climb Bio (CLYM) Competitors

$9.67 -0.21 (-2.16%)

Closing price 03:59 PM Eastern

Extended Trading

$9.64 -0.02 (-0.23%)

As of 05:35 PM Eastern

CLYM vs. RARE, IMNM, RLAY, ZLAB, and KOD

Should you buy Climb Bio stock or one of its competitors? MarketBeat compares Climb Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Climb Bio include Ultragenyx Pharmaceutical (RARE), Immunome (IMNM), Relay Therapeutics (RLAY), Zai Lab (ZLAB), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical presently has a consensus price target of $60.41, suggesting a potential upside of 169.09%. Climb Bio has a consensus price target of $20.30, suggesting a potential upside of 109.99%. Given Ultragenyx Pharmaceutical's higher probable upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Ultragenyx Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical and Ultragenyx Pharmaceutical both had 15 articles in the media. Climb Bio's average media sentiment score of 0.62 beat Ultragenyx Pharmaceutical's score of 0.06 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Climb Bio is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.29	-$575M	-$6.11	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Climb Bio has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Climb Bio's return on equity of -31.45% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Climb Bio	N/A	-31.45%	-30.39%

Summary

Climb Bio beats Ultragenyx Pharmaceutical on 8 of the 15 factors compared between the two stocks.

How does Climb Bio compare to Immunome?

Immunome (NASDAQ:IMNM) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Immunome presently has a consensus price target of $32.82, suggesting a potential upside of 66.93%. Climb Bio has a consensus price target of $20.30, suggesting a potential upside of 109.99%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Climb Bio's return on equity of -31.45% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Climb Bio	N/A	-31.45%	-30.39%

Climb Bio has lower revenue, but higher earnings than Immunome. Climb Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	320.82	-$212.39M	-$2.38	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Immunome had 4 more articles in the media than Climb Bio. MarketBeat recorded 19 mentions for Immunome and 15 mentions for Climb Bio. Immunome's average media sentiment score of 0.79 beat Climb Bio's score of 0.62 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Climb Bio beats Immunome on 8 of the 15 factors compared between the two stocks.

How does Climb Bio compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Relay Therapeutics presently has a consensus price target of $21.80, suggesting a potential upside of 80.61%. Climb Bio has a consensus price target of $20.30, suggesting a potential upside of 109.99%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Climb Bio has lower revenue, but higher earnings than Relay Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	150.65	-$276.48M	-$1.57	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Climb Bio's return on equity of -31.45% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Climb Bio	N/A	-31.45%	-30.39%

Relay Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Climb Bio and 13 mentions for Relay Therapeutics. Climb Bio's average media sentiment score of 0.62 beat Relay Therapeutics' score of 0.56 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio beats Relay Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Climb Bio compare to Zai Lab?

Climb Bio (NASDAQ:CLYM) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Climb Bio has higher earnings, but lower revenue than Zai Lab. Climb Bio is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Zai Lab	$460.16M	4.53	-$175.54M	-$1.62	N/A

Climb Bio has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Zai Lab	-39.29%	-24.32%	-15.52%

Climb Bio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Climb Bio currently has a consensus price target of $20.30, indicating a potential upside of 109.99%. Zai Lab has a consensus price target of $45.83, indicating a potential upside of 149.50%. Given Zai Lab's higher possible upside, analysts clearly believe Zai Lab is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Climb Bio had 10 more articles in the media than Zai Lab. MarketBeat recorded 15 mentions for Climb Bio and 5 mentions for Zai Lab. Climb Bio's average media sentiment score of 0.62 beat Zai Lab's score of 0.28 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Climb Bio beats Zai Lab on 9 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Kodiak Sciences presently has a consensus target price of $42.14, indicating a potential upside of 22.44%. Climb Bio has a consensus target price of $20.30, indicating a potential upside of 109.99%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Climb Bio's return on equity of -31.45% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Climb Bio	N/A	-31.45%	-30.39%

Kodiak Sciences has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 15 mentions for Climb Bio and 12 mentions for Kodiak Sciences. Climb Bio's average media sentiment score of 0.62 beat Kodiak Sciences' score of 0.34 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio beats Kodiak Sciences on 10 of the 14 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$553.53M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-12.39	18.70	20.58	25.11
Price / Sales	N/A	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.88	6.57	9.68	6.60
Net Income	-$59.85M	$24.30M	$3.55B	$335.71M
7 Day Performance	-13.46%	-3.56%	-2.07%	-2.03%
1 Month Performance	5.53%	-7.86%	-3.90%	-1.90%
1 Year Performance	661.18%	51.80%	29.39%	27.36%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	3.4745 of 5 stars	$9.67 -2.2%	$20.30 +110.0%	+665.9%	$553.53M	N/A	N/A	9
RARE Ultragenyx Pharmaceutical	3.2685 of 5 stars	$25.00 -3.1%	$60.41 +141.6%	-32.1%	$2.46B	$673M	N/A	1,371	Insider Trade
IMNM Immunome	3.5029 of 5 stars	$20.88 -5.2%	$32.82 +57.2%	+146.9%	$2.36B	$6.94M	N/A	40	Earnings Report Analyst Upgrade Insider Trade
RLAY Relay Therapeutics	2.987 of 5 stars	$12.20 -4.5%	$20.56 +68.5%	+330.6%	$2.34B	$15.35M	N/A	330	Trending News Analyst Forecast Gap Up
ZLAB Zai Lab	3.97 of 5 stars	$20.59 +1.3%	$45.83 +122.6%	-39.0%	$2.34B	$460.16M	N/A	1,784	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. RARE, IMNM, RLAY, ZLAB, and KOD

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Summary

How does Climb Bio compare to Immunome?

Summary

How does Climb Bio compare to Relay Therapeutics?

Summary

How does Climb Bio compare to Zai Lab?

Summary

How does Climb Bio compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. RARE, IMNM, RLAY, ZLAB, and KOD

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Do insiders & institutionals hold more shares of RARE or CLYM?

Do analysts rate RARE or CLYM?

Which has more volatility and risk, RARE or CLYM?

Does the media prefer RARE or CLYM?

Which has preferable earnings & valuation, RARE or CLYM?

Is RARE or CLYM more profitable?

Summary

How does Climb Bio compare to Immunome?

Do analysts rate IMNM or CLYM?

Is IMNM or CLYM more profitable?

Which has stronger valuation & earnings, IMNM or CLYM?

Does the media prefer IMNM or CLYM?

Which has more risk & volatility, IMNM or CLYM?

Do insiders & institutionals have more ownership in IMNM or CLYM?

Summary

How does Climb Bio compare to Relay Therapeutics?

Do analysts recommend RLAY or CLYM?

Which has preferable earnings and valuation, RLAY or CLYM?

Is RLAY or CLYM more profitable?

Which has more risk and volatility, RLAY or CLYM?

Do insiders & institutionals hold more shares of RLAY or CLYM?

Does the media prefer RLAY or CLYM?

Summary

How does Climb Bio compare to Zai Lab?

Which has stronger valuation & earnings, CLYM or ZLAB?

Is CLYM or ZLAB more profitable?

Which has more volatility & risk, CLYM or ZLAB?

Do analysts rate CLYM or ZLAB?

Do insiders and institutionals believe in CLYM or ZLAB?

Does the media refer more to CLYM or ZLAB?

Summary

How does Climb Bio compare to Kodiak Sciences?

Do analysts recommend KOD or CLYM?

Which has preferable earnings & valuation, KOD or CLYM?

Is KOD or CLYM more profitable?

Which has more risk and volatility, KOD or CLYM?

Do institutionals & insiders believe in KOD or CLYM?

Does the media prefer KOD or CLYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools